Ftse Mib
34.888,79
0,09%
DAX
20.405,92
-0,11%
S&P 500
6.051,09
0,00%
NASDAQ
19.926,72
0,12%
Bitcoin
102.372,50
0,90%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ionis Pharmaceuticals Inc (IONS) Ionis Pharmaceuticals Inc (IONS) Notizie

Ionis Pharmaceuticals Inc

IONS
36,61
-0,40 (-1,08%)
14 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
15/11/202402:34EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202414:55EDGAR2Form 144/A - Report of proposed sale of securities: [Amend]
12/11/202422:17EDGAR2Form 144 - Report of proposed sale of securities
12/11/202422:16EDGAR2Form 144 - Report of proposed sale of securities
12/11/202422:15EDGAR2Form 144 - Report of proposed sale of securities
08/11/202416:52EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
07/11/202413:05PRNUSIonis to present at upcoming investor conferences
06/11/202422:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202417:15EDGAR2Form 8-K - Current report
06/11/202413:01PRNUSIonis Announces Pivotal Phase 3 Trial Design for ION582 in..
06/11/202413:00PRNUSIonis reports third quarter 2024 financial results
04/11/202415:44PRNUSIonis announces FDA acceptance of New Drug Application for..
23/10/202413:05PRNUSIonis to hold third quarter 2024 financial results webcast
21/10/202408:08PRNUSWAINZUA (eplontersen) recommended for approval in the EU by..
18/10/202400:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/10/202400:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/10/202413:30GLOBENew Higher Dose Nusinersen Efficacy and Safety Data..
03/10/202413:00PRNUSNew positive donidalorsen data to be presented at 2024..
02/10/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/10/202413:00PRNUSZilganersen granted U.S. FDA Fast Track designation for..
10/9/202423:19EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/9/202403:10PRNUSIonis announces pricing of $500.3 million public offering
09/9/202422:33EDGAR2Form 8-K - Current report
09/9/202422:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/9/202422:20PRNUSIonis announces proposed public offering of common stock
05/9/202403:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202403:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202403:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202403:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202403:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202403:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/9/202413:30GLOBEBiogen Announces Positive Topline Results from Study of..
04/9/202401:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202413:05PRNUSIonis to present at upcoming investor conferences
06/8/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/8/202422:11EDGAR2Form 144 - Report of proposed sale of securities
05/8/202421:35EDGAR2Form S-8 - Securities to be offered to employees in employee..
01/8/202422:57EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202417:15EDGAR2Form 8-K - Current report
01/8/202413:00PRNUSIonis reports second quarter 2024 financial results
31/7/202415:00PRNUSAlcyone Therapeutics Announces Continued Enrollment Approval..
22/7/202413:00PRNUSIonis announces positive detailed results from the HALOS..
19/7/202414:24PRNUSIonis to hold second quarter 2024 financial results webcast
18/7/202413:00PRNUSIonis completes enrollment in pivotal trial evaluating..
17/7/202423:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202423:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202423:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 37,20 Min: 36,52 Max: 37,37
Chiusura: 37,01

La tua Cronologia

NASDAQ
IONS
Ionis Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network